Go to the list of all blogs
Allana's Avatar
published in Blogs
Feb 16, 2021
3 Ways Blockchain Can Change Financial Markets

3 Ways Blockchain Can Change Financial Markets

Blockchain may be cryptocurrency’s foundation, but that is not the only use case for the technology. Businesses in a variety of industries are discovering new, creative ways to harness blockchain’s powers. Financial markets, in particular, can leverage blockchain’s speed and security to transform daily processes, minimize errors, reduce costs, and produce enhanced experiences for their clients.

Here are three key areas where blockchain can fundamentally alter how business is done in financial markets.

Clearing and Settlement

Clearing and settlement is fundamental to financial markets. Unfortunately, the processes are historically mired in siloed data, general inefficiencies, and frequent inconsistency – byproducts of manual workflows and thorough regulation. The resulting bottlenecks delay settlement and increase costs, especially in multi-party transactions.

Blockchain, on the other hand, facilitates expedient, real-time transactions, condensing settlement time from days to minutes. Better speeds result in cost-savings, and the technology’s immutable ledger means transparency, maintaining trust between participants, reducing risk, and allowing for end-to-end auditing throughout all stages of a transaction.

Know Your Customer

Financial institutions and their customers place a premium on security – especially identity protections. Doing so at scale often means using multiple customer identification management systems, creating additional layers of complexity for employees and clientele. Identity validation quickly turns arduous, increasing the likelihood that customers will endure a compromised user experience.

Blockchain consolidates and stores all client identification documents in a decentralized way, providing valuable peace of mind to all parties concerned. Consumers can prove their identities through a thorough, initial verification process with their bank – upon approval, they can choose to share that information with the appropriate parties, case-by-case. Companies can enjoy significant cost savings as they cut down on administrative work while reaping the benefits of a satisfied customer.

Unlisted Securities

Investing in private companies means performing due diligence – and working with a lot of paper. That can mean long, manual processes on the investor side, creating inevitable delays as discrepancies are settled and details are confirmed for transactions like loans, or changes in share ownership. Small and medium enterprise businesses deal with their own roadblocks, often struggling to access credit or to place themselves within mature, secure investment environments that allow them to raise additional funding.

Blockchain opens new trading and investing opportunities by simplifying the tracking and management of securities information. Small and medium enterprise businesses can digitize issuance of private securities, allowing wider access to investors, giving companies better access to credit, and providing financial information securely and transparently to each party involved.

The financial sector is embracing blockchain’s transformative potential as they streamline daily processes, minimize errors, reduce costs, and enhance their clients’ experiences. Businesses and clients alike are enjoying the benefits. And with new, creative solutions regularly being invented, the revolution is just beginning.

Learn More about the Power of Blockchain – and How to Invest – on Tickeron.com

Access Tickeron’s Academy on tickeron.com to learn more about the cryptocurrency and blockchain revolutions, and even how you can use algorithms and AI to invest. Tickeron has created Artificial Intelligence capable of finding trade patterns and generating investment ideas for the cryptocurrency markets. Start a free trial today on tickeron.com.


Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.